Rite Aid (RAD) Tops Q3 EPS by 5c

Rite Aid (NYSE: RAD) reported Q3 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.55 billion.

Same store sales for the quarter increased 5.4 percent over the prior year, consisting of a 1.6 percent increase in front-end sales and a 7.2 percent increase in pharmacy sales. Pharmacy sales included an approximate 228 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores increased 4.5 percent over the prior year period. Prescription sales accounted for 69.8 percent of total drugstore sales, and third party prescription revenue was 97.6 percent of pharmacy sales.

For earnings history and earnings-related data on Rite Aid (RAD) click here.

You May Also Be Interested In

• Public Service Enterprise (PEG) Misses Q3 EPS by 4c ; Offers Guidance
• ArcelorMittal Q3 2026 analyst consensus: EBITDA seen at $1.97B
• Marriott shares rise 3% in premarket trade after raising full-year forecast